Meridian Bioscience Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $1.49 billion
- Book Value:
- Revenue TTM:
- $333.02 million
- Operating Margin TTM:
- Gross Profit TTM:
- $188.36 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Meridian Bioscience Inc had its IPO on 1986-08-08 under the ticker symbol VIVO.
The company operates in the sector and industry. Meridian Bioscience Inc has a staff strength of 690 employees.
Shares of Meridian Bioscience Inc opened at $33.19 at the start of the last trading session i.e. 2023-06-03.
The stocks traded within a range of $33.14 - $33.3, and closed at $33.21.
This is a -0.03% slip from the previous day's closing price.
A total volume of 0 shares were traded at the close of the day’s session.
In the last one week, shares of Meridian Bioscience Inc have slipped by -42.21%.
Meridian Bioscience Inc's Key Ratios
Meridian Bioscience Inc has a market cap of $1.49 billion, indicating a price to book ratio of 3.9177 and a price to sales ratio of 4.351.
In the last 12-months Meridian Bioscience Inc’s revenue was $333.02 million with a gross profit of $188.36 million and an EBITDA of $92.11 million. The EBITDA ratio measures Meridian Bioscience Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Meridian Bioscience Inc’s operating margin was 22.7% while its return on assets stood at 10.35% with a return of equity of 12.19%.
In Q4, Meridian Bioscience Inc’s quarterly earnings growth was a negative -13% while revenue growth was a negative 13.8%.
Meridian Bioscience Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $0.96 per share while it has a forward price to earnings multiple of 40.6504 and a PEG multiple of 1.33. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Meridian Bioscience Inc’s profitability.
Meridian Bioscience Inc stock is trading at a EV to sales ratio of 4.1783 and a EV to EBITDA ratio of 19.321. Its price to sales ratio in the trailing 12-months stood at 4.351.
Meridian Bioscience Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $456.76 million
- Total Liabilities
- $78.58 million
- Operating Cash Flow
- Capital Expenditure
- $2.65 million
- Dividend Payout Ratio
Meridian Bioscience Inc ended 2023 with $456.76 million in total assets and $0 in total liabilities. Its intangible assets were valued at $456.76 million while shareholder equity stood at $340.54 million.
Meridian Bioscience Inc ended 2023 with $1.10 million in deferred long-term liabilities, $78.58 million in other current liabilities, in common stock, $193.34 million in retained earnings and $120.57 million in goodwill. Its cash balance stood at $74.10 million and cash and short-term investments were $74.10 million. The company’s total short-term debt was $1,954,000 while long-term debt stood at $25.00 million.
Meridian Bioscience Inc’s total current assets stands at $201.53 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $41.57 million compared to accounts payable of $14.41 million and inventory worth $72.66 million.
In 2023, Meridian Bioscience Inc's operating cash flow was $-4654000.00 while its capital expenditure stood at $2.65 million.
Comparatively, Meridian Bioscience Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Meridian Bioscience Inc stock is currently trading at $33.21 per share. It touched a 52-week high of $34.375 and a 52-week low of $34.375. Analysts tracking the stock have a 12-month average target price of $34.
Its 50-day moving average was $31.66 and 200-day moving average was $30.76 The short ratio stood at 7.74 indicating a short percent outstanding of 0%.
Around 134.2% of the company’s stock are held by insiders while 9091.8% are held by institutions.
Frequently Asked Questions About Meridian Bioscience Inc
Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare brands; and urea breath testing for H. pylori under the BreathID and BreathTek brand. This segment also offers respiratory illness assays, such as tests for Group A strep, mycoplasma pneumonia, influenza, and pertussis; and blood chemistry products for LeadCare test kits for the detection of lead in blood. It sells products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, isothermal reagents, nucleotides, and bioresearch reagents used by in vitro diagnostic manufacturers, as well as researchers in immunological and molecular tests for human, animal, plant, and environmental applications. Meridian Bioscience, Inc. was incorporated in 1976 and is headquartered in Cincinnati, Ohio.